UBS Group’s EPIRUS BIOPHARMACEUTICALS INC COM EPRS Stock Holding History

UBS Group’s Portfolio EPRS Stock Details EPRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-8,783	Closed	-$4K	–	8444
2016 Q2	$4K	Buy	+8,783	New	+$14.1K	﹤0.01%	7299
2016 Q1	–	Sell	-1,725	Closed	-$5K	–	8913
2015 Q4	$5K	Buy	1,725 +1,717	+21,463%	+$7.74K	﹤0.01%	7749
2015 Q3	$0	Sell	8 -932	-99%	-$5.47K	﹤0.01%	9137
2015 Q2	$5K	Buy	940 +932	+11,650%	+$6.36K	﹤0.01%	7938
2015 Q1	$0	Sell	8 -2,091	-100%	-$16.8K	﹤0.01%	10240
2014 Q4	$12K	Buy	+2,099	New	+$11K	﹤0.01%	8283

Other funds holding EPRS

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

UBS Group's EPRS Position: Q3 2016 in Review

UBS Group sold out of EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) in Q3 2016, closing a stake of 8,783 shares — an estimated $4K sold.

UBS Group first reported a position in EPRS in Q4 2014 and held it in 6 quarters. The position peaked at $12K in Q4 2014. 3 funds tracked by Wall St. Rank hold EPRS as of Q3 2016.

UBS Group reported no remaining EPIRUS BIOPHARMACEUTICALS INC COM position as of Q3 2016 after selling out during the quarter.
UBS Group sold 8,783 EPIRUS BIOPHARMACEUTICALS INC COM shares in Q3 2016, an estimated $4K.
UBS Group first reported a position in EPIRUS BIOPHARMACEUTICALS INC COM in Q4 2014 and held it in 6 quarters.
UBS Group's EPIRUS BIOPHARMACEUTICALS INC COM position peaked at $12K in Q4 2014.
3 funds tracked by Wall St. Rank held EPIRUS BIOPHARMACEUTICALS INC COM as of Q3 2016.

Based on UBS Group's 13F filing for Q3 2016, filed 14 Nov 2016.